Journal
INTERNAL MEDICINE
Volume 53, Issue 19, Pages 2241-2243Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.53.2023
Keywords
azacitidine; MDS; RAEB; RCUD; single-cycle treatment
Categories
Ask authors/readers for more resources
Recently, 5-azacitidine has been reported to improve the survival of patients with high-risk myelodysplastic syndrome (MDS) and was approved for the treatment of MDS in Japan. We herein report a case of high-risk MDS in which the patient exhibited a hematological improvement three months after the first cycle of 5-azacitidine therapy. The second cycle of 5-azacitidine was not administered due to a severe pulmonary infection. Bone marrow aspiration revealed a decrease in the level of blast cells from 7.0% to 0.7%, and the sub-classification of MDS improved from refractory anemia with excess blasts (RAEB)-1 to refractory cytopenia with unilineage dysplasia. This case demonstrates a possible late effect of 5-azacitidine treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available